Developer docs
API playgroundTry for free, no card

Search company profiles

BlueRun Ventures

Full company profile

uuid00068al

Namestring
BlueRun Ventures
Legal namestring
蓝驰创投
Websiteurl
lanchivc.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

BlueRun Ventures (蓝驰创投) is a China-focused early-stage venture capital firm founded in 2005, headquartered in Beijing with operational presence in Shanghai, Shenzhen, and Hong Kong. The firm manages over 15 billion RMB (~150亿) in long-cycle capital and has invested in more than 200 portfolio companies across technology, consumer, and healthcare sectors, with notable exits including Li Auto (NASDAQ/HKEx 2021), WaterDrop (NYSE 2021), QingCloud (STAR Market 2021), and Monster Charge (NASDAQ 2021). It leads 80% of its deals, often at seed stage, and consistently follows on across subsequent rounds—evidenced by five consecutive rounds in Li Auto from A2 through C and three successive rounds in Zhiyuan Robotics.

The firm is managed by Managing Partners Chen Weiguang (陈维广), Zhu Tianyu (朱天宇), and Cao Wei (曹巍), supported by Partner Liu Ji (刘吉). The team is structured around scientist/PhD backgrounds and former industry operators, providing technical due-diligence capability for deep-tech bets. Since 2024, BlueRun has materially concentrated its thesis on AI and embodied intelligence, leading rounds in humanoid robotics (Galbot/银河通用, Zhiyuan/智元, TARS/它石智航), AI infrastructure (MicroNano Core/微纳核芯 compute-in-memory chips, Lingchu Smart/灵初智能), enterprise AI agents (Yoolee AI/元理智能), and adjacent frontier areas (low-altitude economy via Zero Gravity Aircraft/零重力).

Revenue is generated through standard VC mechanics—management fees on committed capital and carried interest from exits—with no disclosed revenue figures. The firm has built a "BlueRun Family" (蓝驰家族) post-investment platform including the Booming Hub event series (expanding from Beijing to Tokyo in 2025) and Hong Kong government co-programs, formalized a strategic relationship with Hong Kong Investment Corporation (HKIC) via portfolio company Galbot, and brokered a 2025 Eli Lilly strategic partnership for portfolio company LTZ Therapeutics. The firm is private, China-domiciled, and independently owned with no parent company.

Short descriptiontext

BlueRun Ventures (蓝驰创投) is a Beijing-headquartered early-stage venture capital firm managing 15B+ RMB across 200+ Chinese technology, consumer, and healthcare startups, with deep recent focus on AI and embodied intelligence including Moonshot AI, Zhiyuan Robotics, and Galbot.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersChaoyang, China
HQ citystring
Chaoyang
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
early-stage venture capital, startup seed funding, technology venture capital, portfolio investor services, embodied intelligence investment
Industry3 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANACAD
Business Services (B2B) Growth Equity
NAICS code1 code
  • Other Financial Vehicles52599
SIC code1 code
  • Investment Advice6282
Product category
Early-stage venture capital investment
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1基金管理费收入
TypeManaged Services
Description

作为早期创业投资基金,蓝驰创投通过管理费和管理业绩提成(Carried Interest)获取收入

lanchivc.com
2投资组合回报
TypeLicensing Royalties
Description

通过投资于早期创业公司并在后续融资中退出获取投资回报,包括理想汽车、水滴公司、青云科技、怪兽充电等成功上市案例

lanchivc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BlueRun Ventures is an early-stage venture capital firm that invests patient capital into technology startups across AI, embodied intelligence, hard tech, consumer tech, and biotech in China. It supports founders from seed through growth stages with capital, industry resources, and post-investment services through the "BlueRun Family" platform. Revenue is generated through fund management fees and carried interest on long-cycle venture funds.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 2024年度最佳早期创业投资机构TOP2
+2 more records
Product overview1 text field

BlueRun Ventures is a venture capital firm that has been operating in China for 20 years, managing over 150 billion RMB in long-cycle capital. The firm has invested in over 200 startup companies across technology, consumer, and healthcare sectors. BlueRun Ventures does not develop or sell technology products or services; it is an investment firm that provides capital and support to early-stage startups.

Product and service3 records
1Early-stage venture capital investment (seed, angel, Series A and beyond)
CategoryVenture capital investment
Description

Equity investment in early-stage (Series A and earlier) Chinese technology startups, with 80% of investments led by BlueRun; covers AI, embodied intelligence, hard tech, consumer tech, and innovative healthcare/biotech.

2BlueRun Family post-investment support service system (蓝驰家族投后服务体系)
CategoryPortfolio support services
Description

Post-investment value-add services for portfolio companies, including industry matchmaking, financing support, policy/government advisory, and ecosystem events. Available to companies that have received BlueRun investment.

3Booming Hub industry events and community program
CategoryCommunity / events program
Description

BlueRun-hosted industry summits and conferences that bring together founders, portfolio companies, and industry partners for deal sourcing, ecosystem building, and thematic discussions.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1礼来Eli Lilly
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-29
Description

泽安生物医药与礼来达成战略合作,开发髓系细胞衔接器药物治疗自身免疫性疾病

lanchivc.com
2香港特区政府投资推广署
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-09
Description

共同举办「科创企业如何把握香港政策机遇」圆桌交流会,帮助被投企业对接香港资源

lanchivc.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment62 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BlueRun Ventures

Early-stage venture capital investmentlanchivc.com

BlueRun Ventures (蓝驰创投) is a Beijing-headquartered early-stage venture capital firm managing 15B+ RMB across 200+ Chinese technology, consumer, and healthcare startups, with deep recent focus on AI and embodied intelligence including Moonshot AI, Zhiyuan Robotics, and Galbot.

What BlueRun Ventures does

BlueRun Ventures (蓝驰创投) is a China-focused early-stage venture capital firm founded in 2005, headquartered in Beijing with operational presence in Shanghai, Shenzhen, and Hong Kong. The firm manages over 15 billion RMB (~150亿) in long-cycle capital and has invested in more than 200 portfolio companies across technology, consumer, and healthcare sectors, with notable exits including Li Auto (NASDAQ/HKEx 2021), WaterDrop (NYSE 2021), QingCloud (STAR Market 2021), and Monster Charge (NASDAQ 2021). It leads 80% of its deals, often at seed stage, and consistently follows on across subsequent rounds—evidenced by five consecutive rounds in Li Auto from A2 through C and three successive rounds in Zhiyuan Robotics.

The firm is managed by Managing Partners Chen Weiguang (陈维广), Zhu Tianyu (朱天宇), and Cao Wei (曹巍), supported by Partner Liu Ji (刘吉). The team is structured around scientist/PhD backgrounds and former industry operators, providing technical due-diligence capability for deep-tech bets. Since 2024, BlueRun has materially concentrated its thesis on AI and embodied intelligence, leading rounds in humanoid robotics (Galbot/银河通用, Zhiyuan/智元, TARS/它石智航), AI infrastructure (MicroNano Core/微纳核芯 compute-in-memory chips, Lingchu Smart/灵初智能), enterprise AI agents (Yoolee AI/元理智能), and adjacent frontier areas (low-altitude economy via Zero Gravity Aircraft/零重力).

Revenue is generated through standard VC mechanics—management fees on committed capital and carried interest from exits—with no disclosed revenue figures. The firm has built a "BlueRun Family" (蓝驰家族) post-investment platform including the Booming Hub event series (expanding from Beijing to Tokyo in 2025) and Hong Kong government co-programs, formalized a strategic relationship with Hong Kong Investment Corporation (HKIC) via portfolio company Galbot, and brokered a 2025 Eli Lilly strategic partnership for portfolio company LTZ Therapeutics. The firm is private, China-domiciled, and independently owned with no parent company.

BlueRun Ventures firmographics

Firmographics
Name
BlueRun Ventures
Legal name
蓝驰创投
Website
https://lanchivc.com
Company type
Private
Founded year
2005
Operating status
Operating
Short description
BlueRun Ventures (蓝驰创投) is a Beijing-headquartered early-stage venture capital firm managing 15B+ RMB across 200+ Chinese technology, consumer, and healthcare startups, with deep recent focus on AI and embodied intelligence including Moonshot AI, Zhiyuan Robotics, and Galbot.
Ownership category
akta.pro rank

BlueRun Ventures industry classification

Industry
Product category
Early-stage venture capital investment
NAICS
Other Financial Vehicles (52599)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANACAD
Business Services (B2B) Growth Equity

Keywords

  • Early-stage venture capital
  • Startup seed funding
  • Technology venture capital
  • Portfolio investor services
  • Embodied intelligence investment

Where BlueRun Ventures is headquartered

Location

Headquarters

HQ city
Chaoyang
HQ country
China
HQ region
Asia

Offices4 records

Markets served

BlueRun Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. 基金管理费收入: 作为早期创业投资基金,蓝驰创投通过管理费和管理业绩提成(Carried Interest)获取收入
  2. 投资组合回报: 通过投资于早期创业公司并在后续融资中退出获取投资回报,包括理想汽车、水滴公司、青云科技、怪兽充电等成功上市案例

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

BlueRun Ventures product offering

Product offering

Core offering

BlueRun Ventures is an early-stage venture capital firm that invests patient capital into technology startups across AI, embodied intelligence, hard tech, consumer tech, and biotech in China. It supports founders from seed through growth stages with capital, industry resources, and post-investment services through the "BlueRun Family" platform. Revenue is generated through fund management fees and carried interest on long-cycle venture funds.

Product overview

BlueRun Ventures is a venture capital firm that has been operating in China for 20 years, managing over 150 billion RMB in long-cycle capital. The firm has invested in over 200 startup companies across technology, consumer, and healthcare sectors. BlueRun Ventures does not develop or sell technology products or services; it is an investment firm that provides capital and support to early-stage startups.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early-stage venture capital investment (seed, angel, Series A and beyond) Equity investment in early-stage (Series A and earlier) Chinese technology startups, with 80% of investments led by BlueRun; covers AI, embodied intelligence, hard tech, consumer tech, and innovative healthcare/biotech.
  • BlueRun Family post-investment support service system (蓝驰家族投后服务体系) Post-investment value-add services for portfolio companies, including industry matchmaking, financing support, policy/government advisory, and ecosystem events. Available to companies that have received BlueRun investment.
  • Booming Hub industry events and community program BlueRun-hosted industry summits and conferences that bring together founders, portfolio companies, and industry partners for deal sourcing, ecosystem building, and thematic discussions.

Quantifiable outcome

  • 2024年度最佳早期创业投资机构TOP2
  • +2 more outcomes

Companies that use BlueRun Ventures

Customer profile

Named customers16 records

Segments3 records

Ideal customer profiles2 records

BlueRun Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

BlueRun Ventures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • 礼来Eli LillycoreStrategic or Co-development Partner · 29 July 2025泽安生物医药与礼来达成战略合作,开发髓系细胞衔接器药物治疗自身免疫性疾病
  • 香港特区政府投资推广署coreStrategic or Co-development Partner · 9 April 2025共同举办「科创企业如何把握香港政策机遇」圆桌交流会,帮助被投企业对接香港资源

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

BlueRun Ventures competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

BlueRun Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BlueRun Ventures leadership team

Management profile

Number of profiles

Profiles4 records

BlueRun Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BlueRun Ventures M&A and investment

M&A and investment

M&A

Investments62 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BlueRun Ventures

What does BlueRun Ventures do?

BlueRun Ventures is an early-stage venture capital firm that invests patient capital into technology startups across AI, embodied intelligence, hard tech, consumer tech, and biotech in China. It supports founders from seed through growth stages with capital, industry resources, and post-investment services through the "BlueRun Family" platform. Revenue is generated through fund management fees and carried interest on long-cycle venture funds.

Is BlueRun Ventures a public or private company?

BlueRun Ventures is a private company. It is classified as management employee owned and is currently operating.

When was BlueRun Ventures founded?

BlueRun Ventures was founded in 2005.

Where is BlueRun Ventures based?

BlueRun Ventures is headquartered in Chaoyang, China, in the Asia region.

How does BlueRun Ventures make money?

Two revenue lines are on record. 基金管理费收入 is the primary driver. The others are 投资组合回报.

Does BlueRun Ventures have an API?

No public API is recorded for BlueRun Ventures.

What industry is BlueRun Ventures in?

BlueRun Ventures's product category is Early-stage venture capital investment. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52599 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChinaventureMedical AI investor, currently in Hong Kong to recruit PhDs.Hong Kong university medical AI startups are raising capital, with Brain Science Technology completing over $10 million in angel funding and others like Angxin Bio and Si Ruoning Technology securing seed rounds. Mainland investors are now actively entering Hong Kong, with government funds and industrial capital following, as the region's R&D and mainland manufacturing model expands.Fastdata极数苏州自动化柔性化技术及解决方案研发商纵苇科技获得2亿人民币Pre-C++轮融资 – Fastdata极数Zongwei Technology, a Suzhou automation flexible technology developer, raised 200 million RMB in Pre-C++ financing led by Jingwei Venture Capital. The funds will support R&D of core products like intelligent magnetic drive control platforms and planar magnetic levitation, as well as capacity expansion and globalization.JiemianNest Crafts Technology completes hundreds of millions in angel round financing.Nestworks completed a series of angel round financing worth hundreds of millions on September 1st, with investments from Sequoia China, BlueRun Ventures, Zhongding Capital, Xiangfeng Investment, Yuanjing Capital, and others. Gao Hu Capital acted as exclusive financial advisor. The funds will support R&D of new desktop-level intelligent CNC, AI software iteration, creator ecosystem, and global expansion.ChinaventureCao Xi is raising US dollars again, this time 500 million.Multiple venture capital firms are raising dollar funds again, with Monolith launching a $500 million AI-focused fund. Other firms like IDG, Sequoia China, and Source Code have also announced new rounds, though the return of capital remains uncertain.Pedaily刘宇首次揭开Vivix面纱Liu Yu, a PhD graduate born in 1995 who spent nine years at AI company SenseTime, has founded Vivix, a startup focused on real-time interactive multimodal AI models, after resigning in October 2024. Vivix has completed five rounds of financing in 2025, securing investments from IDG Capital, Sequoia China, BlueRun Ventures, Wuyuan Capital, Monolith Capital, JD.com, and Alibaba, reaching a valuation of $1.32 billion. The company has developed two models—Vivix-A1 for interactive AI characters and Vivix-W1 for interactive storytelling—and plans to launch these models and their APIs soon while exploring B-end API commercialization based on token pricing.36krthe "last millimeter" for robots to interact with the physical worldChina's dexterous hand sector saw record financing in 2026, with total funding exceeding 25 billion RMB in the first half, up 48% year-over-year. AGILINK surpassed a $1 billion valuation, and Lingxin Qiaoshou targeted a $6 billion round. The industry faces price wars and unresolved bottlenecks in hardware, data, and deployment.Fastdata极数Shenzhen-based embodied intelligence robot developer Moqi Intelligent has completed over 1 billion yuan in angel round financing - Fastdata.Moqi Intelligent, a Shenzhen-based embodied intelligence robot developer, completed over 1 billion yuan in angel round financing, valuing the company at more than 7 billion yuan. Investors include Alibaba, Tencent, BlueRun Ventures, and others.36kr2000 Entrepreneur from Zhejiang University Secures Tens of Millions in Financing Led by GAO Bingqiang and BlueRun Ventures, Enters AI Intelligent Imaging Field via LongStarSense Technology completed Angel+ and Angel++ financing rounds totaling tens of millions of yuan, led by Gao Feng Patient Capital and BlueRun Ventures. The funds will support R&D of intelligent imaging technologies and new product development. The company's Vizta intelligent telescope, a lightweight AI-assisted lens, has achieved positive cash flow and is being used for bird-watching and stargazing.PedailyFirst release | A PhD from the post-90s generation takes the helm, raising hundreds of millions in angel and round financing.Kaiwuji, an AI4Materials company founded in September 2025 by PhD graduates born in the 1990s, has completed an angel+ financing round raising several hundred million yuan, led by Monolith with participation from Guanghe Venture Capital, Jifu Asia, Hillhouse Capital, IDG Capital, BlueRun Ventures, BV Baidu Ventures, and L2F Light Source Entrepreneur Fund. The round comes just five months after the company's hundred million-level angel round in November 2024, marking two consecutive financing rounds within half a year. The company, led by founder Dr. Lu Ziheng (a 1992-born PhD from HKUST with postdoc experience at Cambridge and former Microsoft Research tenure), focuses on building a full-stack material innovation platform combining AI model scaling, experimental verification, and ton-level mass production.SmartheyNest Crafts Technology has received first-round investment from Sequoia China and BlueRun Ventures, focusing on the smart desktop CNC market.NestWorks Technology, a consumer-grade desktop CNC company established in November 2025 as a spin-off from Elephant Robotics, has completed its first round of financing from Sequoia China and BlueRun Ventures. The company focuses on smart desktop-level CNC equipment, targeting individual makers, educational institutions, and small and micro manufacturing enterprises with industrial-grade precision processing solutions. The investment represents early-stage backing from two prominent venture capital firms for a niche manufacturing technology startup.